Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Bristol-Myers Squibb

Eliquis and Opdivo sales help offset declines for established products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb
2Q Revenues: $5.7 billion (+11%)
2Q Earnings: $382.0 million (earnings were $922 million 2Q17)
YTD Revenues: $10.9 billion (+8%)
YTD Earnings: $1.9 billion (-23%)
Comments: Eliquis sales were up 40% to $474 million. Opdivo sales were $432 million, up 36%. Orencia sales were up 9% to $711 million. Sprycel sales were up 6% to $535 million. Yervoy were down 2% to $315 million. Baraclude sales were down 34% to $179 million. Sustiva Franchise sales were down 61% to $73 million. Reyataz Franchise sales were $117 million, down 38%. Hepatitis C Franchise sales were down 89% to 12 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters